Control of Marek's Disease in the Netherlands. II. Field Trials on Vaccination with an Avirulent Strain (CVI 988) of Marek's Disease Virus

Bh, Rispens; H, van Vloten; Mastenbroek, N; Jl, Maas; Ka, Schat

doi:10.2307/1588906

Cited by 119 publications

(56 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike human diseases caused by herpesviruses, MD is the first lymphoproliferative disease which is effectively controlled and prevented by a vaccination strategy. The introduction of successful MD vaccines derived from either attenuated serotype 1 MDV (MDV1) (16), avirulent MDV1 (29,30), or MDV2 or MDV3 (herpesvirus of turkeys [HVT]) (24) has been a singular achievement both for agricultural development and as a model system for studying the prevention of cancer in the natural host. Thus, research on the pathogenesis and immunology of MD has significant importance for comparative medicine in humans and animals.…”

mentioning

confidence: 99%

“…However, since the application of global MD vaccination 30 years ago, oncogenic MDV continuously trends toward increasing virulence, and more virulent MDV strains have emerged. Some of these can break through vaccinal protection, such as very virulent MDV (vvMDV) and very-virulent-plus MDV (vvϩMDV), which seriously threaten the effectiveness of the existing MD vaccines (16,22,24,29,30,39). In some countries or areas, MD vaccine failures caused by vvMDV have become common again, causing huge economic losses, and this is becoming a serious problem in poultry.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

Gan

Jin

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

The most common lymphoproliferative disease in chickens is Marek's disease (MD), which is caused by the oncogenic herpesvirus Marek's disease virus (MDV). The emergence of hypervirulent pathotypes of MDV has led to vaccine failures, which have become common and which have resulted in serious economic losses in some countries, and a revaccination strategy has been introduced in practice. The mechanism by which revaccination invokes superior immunity against MD is unknown. After field trials which showed that revaccination provided protection superior to that provided by a single vaccination were performed, experiments were conducted to explore the interaction between revaccinated chickens and MDV. The results showed that the chickens in the revaccination groups experienced two consecutive productive infections but that the chickens in the singlevaccination groups experienced one productive infection, demonstrating that revaccination of viruses caused the chickens to have productive and then latent infections. Revaccination of the virus induced in the chickens a higher and a longer temporary expansion of the CD8 ؉ , CD4 ؉ , and CD3 ؉ T-lymphocyte subpopulations, stronger peripheral blood lymphocyte proliferative activity; and higher levels of neutralizing antibody than single vaccination. These findings disagree with the postulate that MDV antigens persist, stimulate the immune system, and maintain a high level immunity after vaccination. The suppression of productive infection by maternal antibodies in chickens receiving the primary vaccination and a lower level of productive infection in the revaccination groups challenged with MDV were observed. The information obtained in this study suggests that the productive infection with revaccinated MDV in chickens plays a crucial role in the induction of superior immunity. This finding may be exploited for the development of a novel MD vaccine that results in the persistence of the antigen supply and that maintains a high level of immunity and may also have implications for other viral oncogenic diseases in humans and animals.Herpesviruses are important pathogens associated with a wide range of diseases in human and animals. Marek's disease (MD) is an important, ubiquitous, contagious, and oncogenic disease in chickens caused by Marek's disease virus (MDV), an alphaherpesvirus (12). Apart from its importance in the poultry industry and for animal welfare (5), MD makes a significant contribution to our understanding of herpesvirus-associated oncogenicity due to the many MD lymphomas with a biological nature similar to that of the lymphoid neoplasia associated with human herpesviruses, such as Epstein-Barr virus (17). Studies have suggested that MD is a natural model for lymphomas that overexpress the Hodgkin's disease antigen, CD30 (7), and MD in small animals provides a well-defined model of general tumorigenesis and virus-induced lymphomagenesis (5,7,12,17,22). Unlike human diseases caused by herpesviruses, MD is the first lymphoproliferative disease which is effective...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

Gan

Jin

et al. 2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…The complete genome sequences of MDV, GaHV-3, and HVT are available, and the MDV genome is approximately 177 kbp in length, encoding at least 103 proteins (43). MD caused by oncogenic MDV can successfully be prevented by vaccination with the genetically and antigenically closely related and nonpathogenic GaHV-3 and HVT, or by using attenuated MDV strains (33,45,46).…”

mentioning

confidence: 99%

The Protein Encoded by the U _S 3 Orthologue of Marek's Disease Virus Is Required for Efficient De-Envelopment of Perinuclear Virions and Involved in Actin Stress Fiber Breakdown

Schumacher

Tischer

Trapp

et al. 2005

J Virol

109

View full text Add to dashboard Cite

“…The virus strains used were the oncogenic strains BC1 (Spencer et al, 1972), JM (Sevoian et al, 1962) and Md5 (Witter et aL, 1980) of MDV1, the non-oncogenic strains C2 (Kato et al, 1970) and CVI988 (Rispens et al, 1972) of MDV2, strains HPRS24 (Biggs & M ilne, 1972) and SB 1 (Schat & Calnek, 1978) of MDV2 and vaccine strains O1 (Ono et al, 1974) and FC126 (Witter et al, 1970) of HVT. These viruses were propagated in primary chicken embryo fibroblasts (CEF) as described previously (Ikuta et al, 1981).…”

Section: Methodsmentioning

confidence: 99%

Identification of Virus-specific Polypeptides by Monoclonal Antibodies against Serotype 2 Marek's Disease Virus

Nakajima

Shibayama²,

Ikuta³

et al. 1989

Journal of General Virology

View full text Add to dashboard Cite

SUMMARYA total of 41 antibody-secreting hybridoma cells against the HPRS24 strain of Marek's disease virus (MDV) type 2 (MDV2) have been isolated. Of these monoclonal antibodies (MAbs), 24 were found by immunofluorescence tests to react specifically with MDV2-infected cells, but not MDV type 1 (MDV1)-or herpesvirus of turkeys (HVT)-infected cells, while eight reacted with MDV1-or MDV2-infected cells and nine with MDVI-, MDV2-or HVT-infected cells. By using these MAbs, seven classes of MDV type-specific or cross-reactive polypeptides were characterized by immunoprecipitation followed by SDS-PAGE. Among them, a 28K/32K glycoprotein differed from the previously identified gA and gB. The 28K/32K glycoprotein was found on the surface of MDV2-infected cells and in the cytoplasm by an immunofluorescence test with MAbs. In addition, a cross-reactive polypeptide of 25K/29K was also detected in MDVl-infected cells with MAbs reactive with the 28K/32K glycoprotein of MDV2.

show abstract

Control of Marek's Disease in the Netherlands. II. Field Trials on Vaccination with an Avirulent Strain (CVI 988) of Marek's Disease Virus

Cited by 119 publications

References 4 publications

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

The Protein Encoded by the U _S 3 Orthologue of Marek's Disease Virus Is Required for Efficient De-Envelopment of Perinuclear Virions and Involved in Actin Stress Fiber Breakdown

Identification of Virus-specific Polypeptides by Monoclonal Antibodies against Serotype 2 Marek's Disease Virus

Contact Info

Product

Resources

About

Control of Marek's Disease in the Netherlands. II. Field Trials on Vaccination with an Avirulent Strain (CVI 988) of Marek's Disease Virus

Cited by 119 publications

References 4 publications

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

Revaccination with Marek's Disease Vaccines Induces Productive Infection and Superior Immunity

The Protein Encoded by the U S 3 Orthologue of Marek's Disease Virus Is Required for Efficient De-Envelopment of Perinuclear Virions and Involved in Actin Stress Fiber Breakdown

Identification of Virus-specific Polypeptides by Monoclonal Antibodies against Serotype 2 Marek's Disease Virus

Contact Info

Product

Resources

About

The Protein Encoded by the U _S 3 Orthologue of Marek's Disease Virus Is Required for Efficient De-Envelopment of Perinuclear Virions and Involved in Actin Stress Fiber Breakdown